type IV hypersensitivity disease

Summary

type IV hypersensitivity disease (MONDO:0002459) is a disease and 1 clinical trial. A subtype of hypersensitivity reaction disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	type IV hypersensitivity disease
Mondo ID	MONDO:0002459
DOID	DOID:2916
NCIT	C3115
UMLS	C0020522
MedGen	9371
Is cancer (heuristic)	no

Also known as: delayed hypersensitivity reaction · delayed-type hypersensitivity · delayed-type hypersensitivity response · disorder of type IV hypersensitivity · DTH · type 4 hypersensitivity reaction · type IV hypersensitivity · type IV hypersensitivity reaction

Disease family

This is a subtype of hypersensitivity reaction disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › hypersensitivity reaction disease › type IV hypersensitivity disease

Related subtypes (9): allergic disease, hypersensitivity vasculitis, type III hypersensitivity disease, IgE responsiveness, atopic, immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome, progestogen hypersensitivity, type II hypersensitivity reaction disease, pseudoallergy, anaphylaxis

Subtypes (3): cryoglobulinemia, autoimmune lymphoproliferative syndrome, serum sickness

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03625219	Not specified	COMPLETED	Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CHEMBL15720	0	1